Tag: Ustekinumab
Comparable safety profiles of biological therapies in elderly patients with IBD
Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease
Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis
Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease
Potential biomarker discovered for treatment response to ustekinumab
Explaining arthropathy development through IL-4 and IL-13 blockade
Risankizumab superior to ustekinumab in skin histopathology scores
Tapering biologics: No alarming signs of increased anti-drug antibodies
HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario
Ustekinumab: highly efficacious in PSA independent of methotrexate
Ustekinumab treat-to-target strategy offers long-term alternative for standard-of-care in CD
Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD
Ustekinumab safe and effective in elderly CD patients
Risk of hospitalisation and surgery linked to IBD biological
Allergies: an underrated factor in alopecia pathogenesis
Bimekizumab in psoriasis: Up-and-coming
First randomised T2T trial using endoscopy to guide dose escalation
Biologics in HS – a growing armamentarium
Psoriasis therapy for children and pregnancies
IL-17A and IL-17F blockade remarkably effective in psoriasis
Vedolizumab, adalimumab, and golimumab compared
Ustekinumab in CD: a T2T trial
Subcutaneous ustekinumab as maintenance therapy in UC
Impact of biologicals on faecal microbiota
Lowest risk of infection after therapy with an IL-12/IL-23 blocker
Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib
Biologics: increasingly used in paediatric dermatology
Ustekinumab is safe and effective in ulcerative colitis: 2-year data
Subcutaneous ustekinumab as maintenance therapy in UC
New targets and biologics for cutaneous lupus erythematosus
Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients
Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies
